BeiGene’s pathfinding CFO Liang to retire
Update comes as China bellwether reveals trial delays, reports rise in revenue
Howard Liang, who has played an integral role in bringing global prominence to the China biotech sector over the past five years, is retiring as BeiGene CFO and chief strategy officer. The news came as BeiGene announced its 3Q20 financial results, in which the company also revealed a delay for clinical trials of programs partnered with Amgen, including KRAS inhibitor sotorasib.
Liang opened the eyes of other China-based biotechs with global ambitions when he left Leerink, where he was managing director and head of biotechnology equity research, for BeiGene in 2015. Multiple companies have since followed suit, including Hua Medicine Ltd. (HKEX:2552), which hired George Lin from Bank of America; and Zai Lab Ltd. (NASDAQ:ZLAB), which hired Citigroup’s Billy Cho...